Sandoz has accused Amgen of ‘dragging the chain’ as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
A group of Australia’s leading beef and dairy companies has failed to strike-out a suit alleging their genetic testing system for cattle infringes the patent of a US genomics company, with a judge rejecting objections to the phrase ‘further or in the alternative’.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis’ appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
Green iron start-up Element Zero has lost its latest bid to set aside search orders in a case by Fortescue alleging former employees misappropriated its process for carbon dioxide-free iron.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.
Generic drug maker Sun Pharma has succeeded in invalidating Otsuka Pharmaceutical’s patent for an injectable, controlled release form of the Japanese drug maker’s top-selling antipsychotic Abilify.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.
Element Zero has denied claims that three former Fortescue employees, including one executive, misused confidential information and developed a green iron process on the company dime.